Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New quick MRI could slash prostate cancer scan costs by 30%

NCT ID NCT05046782

Diagnosis Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled This study
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study aimed to test an abbreviated MRI method (using restriction spectrum imaging plus T2-weighted images) for detecting prostate cancer, comparing it to the standard multiparametric MRI. The goal was to see if the faster, cheaper scan could find cancer just as well, while avoiding contrast dye and reducing scan time and cost. However, the study was withdrawn before any participants were enrolled, so no results were obtained.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
restriction spectrum imaging (RSI) MRI device
What this could lead to
If successful, this could provide a faster, cheaper, and safer MRI option for prostate cancer detection, reducing scan time and cost by up to 40%.
What could go wrong
The study was withdrawn before enrolling any participants, so no results are available. The approach may not prove as accurate as standard MRI in practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Expected to start

Feb 2026

An estimate. Start dates often move.

Expected to finish

Feb 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

-Inclusion Criteria: Primary Objective Cohort * Treatment naïve patients with histologically confirmed clinically significant prostate cancer (defined as Gleason score \> 3+4 and a maximum cancer core length of \> 4mm (42)) with a clinical indication for prostate mpMRI for pre-treatment tumor detection and staging * Patients with anticipated clinical follow-up who are anticipated to undergo surgery at MD Anderson. Secondary Objective Cohort * Treatment naïve patients with histologically confirmed intermediate risk prostate cancer (defined as Gleason score \> 3+4 and a maximum cancer core length of \> 4mm (42)) with a clinical indication for prostate mpMRI, who are to undergo target selection for fusion guided biopsy. * Patients who are anticipated to undergo fusion guided biopsy at MD Anderson. Exclusion Criteria: * Patients who have already received androgen deprivation therapy or undergone prior surgery, radiotherapy or focal ablative therapies to the prostate * Patients whose weight exceeds 400 pounds * Patients allergic to gadolinium * Patients with pacemakers or other implantable devices or conditions that are a contraindication to MRI * Patients with conditions precluding MR imaging at 3T * Patients less than 18 years of age * Patients unable to provide informed consent * Patients unable to tolerate an endorectal coil * Patients who have undergone prostate biopsy less than 6 weeks prior to their MRI

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Prostate cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Prostate cancer

More trials for these conditions

Other studies related to the condition(s) this trial covers.